Effect of AFPGC Immune-Microenvironment and Resistance to Immunotherapy.

Xiaoyi Chong,Jialin Lu,Yakun Wang,Xiaotian Zhang

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e16041

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:e16041 Background: Alpha-fetoprotein producing gastric cancer (AFPGC) is a rare subtype GC with high with high morbidity and mortality rates. Even though immunotherapy has become the cornerstone of first-line treatment, our previous results suggest that AFPGC was resistant to immunotherapy, standard regimen remains unclear. It is warranted to explore precision immunotherapy strategies for AFPGC. Methods: A retrospective cohort of 98 patients with gastric cancer receiving mono-immunotherapy was included. Kaplan-Meier survival plots for PFS and OS were generated based on the AFP levels. Log-rank tests were used to compare the survival curves. Chi-square test was used to analyze the differences in the efficacy of immunotherapy between patients with different levels of AFP. AFPGC in vivo models were constructed, and after in vivo administration, RNA-seq, flow cytometry, and Western blot were used to explore and validate the features of the AFPGC microenvironment and explore immunotherapy combination strategies. Results: Retrospectively analysis demonstrated that the response of mono-immunotherapy in AFPGC was inferior to that in non-AFPGC (ORR: 16.7% vs 29.3%; DCR: 33.0% vs 55.4%). The response of the subcutaneous transplant tumor model with AFP overexpression to PD-1 antibody was significantly reduced. Meanwhile, RNA-seq results from the secondary PD-1 antibody resistant model showed that the mRNA level of AFP was significantly upregulated in the resistant model. RNA-seq results from transplant tumors of AFPGC compared to nAFPGC revealed that the differentially expressed genes were significantly enriched in pathways related to neutrophil chemotaxis and angiogenesis. Flow cytometry confirmed that the proportion of neutrophils in AFPGC was significantly higher than that in nAFPGC. SB265610 (neutrophil chemokine receptor inhibitor) combined with PD-1 antibody and apatinib (anti-angiogenesis) plus PD-1 antibody were administrated in animal models. Both of the regimens could release the primary resistance to PD-1 antibody. Based on these preclinical findings, we designed and conducted a clinical study (NCT04609176) to explore the reponse of apatinib combined with PD-1 antibody in AFPGC. Primary endpoints were achieved and will be announced in the near future. Typical case is depicted as follows: A 79 years old male patients diagnosed with low-differentiated adenocarcinoma of GC, AFP: 135220 ng/ml. After fail in chemotherapy, patients were treated with third-line apatinib 250mg po d1-d21, PD-1 monoclonal antibody 200mg d1, q21d for 6 cycles. Patient was evaluated as partial response (PR) for 4 months and AFP sharply decreased to 945 ng/ml. Conclusions: AFPGC is resistant to PD-1 monoclonal antibody. Combined treatment with SB265610 or apatinib can alleviate or reverse the resistance, making it the most promising treatment regimen for AFPGC.